Tumor heterogeneity (36–38) is the leading driver of drug resistance and disease progression in the post-EGFR-TKI treatment course, and the underlying factor that liquid biopsy and puncture pathology may not reflect the overall truly mutated status of the lesion in the process of disease genetic identification, therapeutic efficacy monitoring and follow-up. Here, EGFR is linked to neoplasm.